ADVERTISEMENT

Tatva Chintan Pharma Q1 Results Review - Yet Another Cut In FY25 Guidance: Nirmal Bang

Demand and pricing recovery and timely commercialisation of projects are key monitorables, in brokerages' view.

<div class="paragraphs"><p>Tatva Chintan Pharma Chem Ltd.(Source: Company)</p></div>
Tatva Chintan Pharma Chem Ltd.(Source: Company)
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
To continue reading this story
You must be an existing Premium User
OUR NEWSLETTERS
By signing up you agree to the Terms & Conditions of NDTV Profit